Amelie Ramirez, DrPH, MPH, of The University of Texas Health Science Center at San Antonio has won the 2023 Association of American Cancer Institutes (AACI) Cancer Health Equity Award. The award recognizes exceptional leadership in promoting health equity, mitigating cancer disparities, and advocating for diversity and inclusion at a cancer center. Ramirez is associate director […]
Share This Story
Multinational study identifies immune resilience as a factor that influences life span, HIV/AIDS, flu, sepsis mortality, recurrent skin cancer and COVID-19 mortality Researchers from The University of Texas Health Science Center at San Antonio, working with collaborators in five countries, today revealed that the capacity to resist or recover from infections and other sources of […]
Share This Story
Montaser Shaheen, MD, Hematology Oncology, professor of oncology and director of the immunotherapy program at the UT Health San Antonio Mays Cancer Center, was interviewed for this story. Read More
Share This Story
Mark Bonnen, MD, chair, Radiation Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news story. Read More
Share This Story
The Mays Cancer Center at the University of Texas Health Science Center at San Antonio has ranked fourth in the nation for clinical trial enrollments among over a thousand institutions that are members of SWOG Cancer Research Network, formerly known as the Southwestern Oncology Group. SWOG is an organization supported by the National Cancer […]
Share This Story
Andrew Brenner, MD, Neurosurgery, and William Kelly, MD, Hematology & Oncology, both of the UT Health San Antonio Mays Cancer Center, were mentioned in this story via the word ‘conducted,’ which links to the university’s press release about the Mays Cancer Center conducting the only clinical trial in America of a specific drug combination for […]
Share This Story
Kate Lathrop, MD, Hematology & Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news segment. Watch Now
Share This Story
An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer […]
Share This Story
Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to low long-term survival rates, with only 7.2% of patients surviving beyond […]
Share This Story
Virginia Kaklamani, MD, Medicine, Hematology & Oncology, UT Health San Antonio Mays Cancer Center, was interviewed for this news segment about new recommendations for women receiving mammograms. Watch Now
Share This Story